Cosmos Health (NASDAQ:COSM) Issues Earnings Results, Misses Expectations By $0.11 EPS

Cosmos Health (NASDAQ:COSM) issued its earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.11), FiscalAI reports. Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%.The company had revenue of $18.99 million for the quarter, compared to analyst estimates of $19.42 million.

Cosmos Health Price Performance

Cosmos Health stock traded up $0.00 during trading hours on Tuesday, hitting $0.21. The stock had a trading volume of 2,288,473 shares, compared to its average volume of 4,473,561. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.08 and a quick ratio of 0.92. The stock has a market capitalization of $12.40 million, a price-to-earnings ratio of -0.32 and a beta of 4.80. Cosmos Health has a 1-year low of $0.16 and a 1-year high of $1.32. The stock’s fifty day moving average is $0.23 and its two-hundred day moving average is $0.30.

Insiders Place Their Bets

In other Cosmos Health news, CFO Georgios Terzis acquired 168,135 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were acquired at an average cost of $0.25 per share, for a total transaction of $42,033.75. Following the transaction, the chief financial officer directly owned 2,235,398 shares of the company’s stock, valued at approximately $558,849.50. This represents a 8.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Grigorios Siokas acquired 766,284 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was acquired at an average cost of $0.18 per share, for a total transaction of $137,931.12. Following the completion of the purchase, the chief executive officer owned 14,248,092 shares in the company, valued at $2,564,656.56. The trade was a 5.68% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders bought 2,204,138 shares of company stock valued at $457,137. Company insiders own 26.15% of the company’s stock.

Hedge Funds Weigh In On Cosmos Health

Several hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in shares of Cosmos Health by 260.5% in the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock valued at $167,000 after purchasing an additional 241,775 shares in the last quarter. Citadel Advisors LLC increased its stake in shares of Cosmos Health by 133.1% during the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after purchasing an additional 128,776 shares in the last quarter. Finally, XTX Topco Ltd increased its stake in shares of Cosmos Health by 52.1% during the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after purchasing an additional 34,117 shares in the last quarter. 12.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.